Le Lézard
Classified in: Health
Subject: TRI

Qilu Pharmaceutical Releases Latest Results of QL1604 plus Chemotherapy as First-Line Treatment for Patients with Advanced Cervical Cancer in the Phase II Study at ESMO Asia Congress 2022


JINAN, China, Dec. 4, 2022 /PRNewswire/ -- Qilu Pharmaceutical, one of the leading vertically integrated pharmaceutical companies in China that develops, manufactures, and distributes both finished formulations and Active Pharmaceutical Ingredients, announced that the results of the phase II study evaluating QL1604 plus chemotherapy as first-line treatment for patients with recurrent or metastatic (R/M) cervical cancer were released on 4 December 2022 in oral presentation (Proffered Paper, 179O) at the European Society for Medical Oncology (ESMO) Asia Congress 2022.

Cervical cancer is the fourth most frequently diagnosed cancer and the fourth leading cause of cancer death in women worldwide. Patients with R/M cervical cancer have a poor prognosis and the 5-year survival rate is less than 20%. Although immune checkpoint inhibitors (ICIs) have shown clinical activity in R/M cervical cancer as second-line treatment, the studies on ICIs given in the first-line setting are limited.

QL1604 is a highly selective, humanized monoclonal antibody that binds to PD-1. This is a phase II, open-label, single-arm study of QL1604 plus chemotherapy in patients with R/M cervical cancer (NCT04864782). Eligible patients received QL1604 200 mg plus chemotherapy (paclitaxel and cisplatin/carboplatin) once every 3 weeks (Q3W) for up to 6 cycles, and then QL1604 200 mg Q3W for maintenance therapy until disease progression or other discontinuation events.

As of the data cutoff, 46 patients with R/M cervical cancer and naïve to systemic treatment were enrolled at 12 sites in China. Twenty (43.5%) patients previously underwent surgery and 40 (87%) patients previously received radiotherapy. Thirty-nine (84.8%) patients had recurrent disease and 7 (15.2%) patients had stage IV disease.

The median follow-up time was 12.91 months. A total of 8 (17.4%) patients achieved complete response and 19 (41.3%) patients achieved partial response, resulting in an objective response rate of 58.7% (27/46). The disease control rate was 84.8% (39/46). The median duration of response was 9.6 months (95% CI: 5.5, NE). The median progression-free survival was 8.1 months (95% CI: 5.7, 14.0). The overall survival was not reached.

QL1604 plus chemotherapy demonstrated a manageable safety profile, which was consistent with that reported for chemotherapy or anti-PD-1 therapy. The most common treatment-related adverse event was white blood cell count decreased.

Ms. Xiaoyan Kang, Head of Qilu Pharmaceutical clinical research center, stated, "We are pleased to release the latest study results of QL1604 plus chemotherapy as first-line treatment for patients with advanced cervical cancer. QL1604 plus chemotherapy showed promising antitumor activity and manageable safety profile as first-line treatment for women with R/M cervical cancer. Further investigations in this setting are ongoing."

SOURCE Qilu Pharmaceutical Co., Ltd.


These press releases may also interest you

at 13:36
Canadian Blood Services is hosting a three-day pop-up barber shop event to raise awareness about the need for stem cell donors and help interested individuals register to become stem cell donors. The event will encourage young males between the ages...

at 13:27
Quest Diagnostics , the world's leading provider of diagnostic information services, today announced that it has been selected as one of FORTUNE's World's Most Admired Companies in 2023 for the ninth consecutive year. ...

at 13:20
MedSpa Partners Inc. ("MSP") is proud to welcome Dr. Shino Bay Aguilera and his team to its top-tier North American medical aesthetics platform. Based in Fort Lauderdale, Florida, Shino Bay Cosmetic Dermatology & Laser Institute has been providing...

at 13:17
A new double-blind, randomized, placebo?controlled study reveals a natural, safe and effective path for women who face hair thinning, a condition commonly experienced in menopause. The new study, conducted with menopausal women, found oral intake of...

at 13:05
Berkeley-based precision medicine solutions provider Newomics Inc. has announced the commercial placement of its 100th mass spectrometry front-end system, which has contributed to successful customer applications in the development of biotherapeutics...

at 13:00
The dermatology devices market size reached USD 5.46 Billion in 2021 and is expected to register a CAGR of 12.7% during the forecast period, according to latest analysis by Emergen Research. One key factor driving market revenue growth is rising...



News published on 4 december 2022 at 04:00 and distributed by: